A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Xilio Development Inc.
Start Date
August 29, 2024
End Date
August 22, 2029
Awarded By
Xilio Development Inc.
Start Date
August 29, 2024
End Date
August 22, 2029